Improved reference panels that account for the unique diversity in African American genetic backgrounds and use of imputation to overcome obstacles with the homology between the MYLK and MYLKP1 promoter regions, may reveal unique therapeutic targets for cancer and elucidate mechanisms and pathways that contribute to greater colon cancer severity in African American populations [50]. The gene discussed is MYLK; the disease is malignant colon neoplasm.